GGrantIndex
← Leaderboards

Jeffrey N Bruce

Columbia University Health Sciences

$6,985,161
Attributed
$9,434,579
Total exposure
6
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $880.5K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,434,579 · 6

By mechanism

R01$8,897,592 · 3
M01$536,987 · 3

Top collaborators

Most similar at Columbia University Health Sciences

Same institution · by research overlap

Others in their field

Top investigators on “Operative Surgical Procedures

Research focus

Operative Surgical ProceduresAnimal ModelTumorResponseExcisionRecurrenceSamplingBrainGlioblastomaMagnetic Resonance ImagingTopotecanBrain NeoplasmsDrug Delivery SystemsGliomaChemotherapyInnovationBrain TissueMethodologyBiopsyMalignant GliomaImplantConvectionNeoplastic CellClinical Trials

Grant awards (26)

Single Cell Analysis of the Infiltrative Margins of Glioblastoma and Post Treatment Recurrence$648,602
R01 · FY2025 · NS · contact PI
Single Cell Analysis of the Infiltrative Margins of Glioblastoma and Post Treatment Recurrence$630,987
R01 · FY2024 · NS · contact PI
Single Cell Analysis of the Infiltrative Margins of Glioblastoma and Post Treatment Recurrence$652,348
R01 · FY2023 · NS · contact PI
Single cell analysis of the infiltrative margins of glioblastoma and post-treatment recurrence$348,948
R01 · FY2021 · NS
Single cell analysis of the infiltrative margins of glioblastoma and post-treatment recurrence$348,514
R01 · FY2020 · NS
Single cell analysis of the infiltrative margins of glioblastoma and post-treatment recurrence$348,234
R01 · FY2019 · NS
Single cell analysis of the infiltrative margins of glioblastoma and post-treatment recurrence$348,236
R01 · FY2018 · NS
CHRONIC CONVECTION ENHANCED DELIVERY (CED) OF TOPOTECAN FOR GLIOBLASTOMA$532,270
R01 · FY2017 · CA · contact PI
Single cell analysis of the infiltrative margins of glioblastoma and post-treatment recurrence$348,258
R01 · FY2017 · NS
CHRONIC CONVECTION ENHANCED DELIVERY (CED) OF TOPOTECAN FOR GLIOBLASTOMA$536,623
R01 · FY2016 · CA · contact PI
CHRONIC CONVECTION ENHANCED DELIVERY (CED) OF TOPOTECAN FOR GLIOBLASTOMA$541,974
R01 · FY2015 · CA · contact PI
CHRONIC CONVECTION ENHANCED DELIVERY (CED) OF TOPOTECAN FOR GLIOBLASTOMA$576,100
R01 · FY2014 · CA · contact PI
CHRONIC CONVECTION ENHANCED DELIVERY (CED) OF TOPOTECAN FOR GLIOBLASTOMA$88,962
R01 · FY2013 · CA · contact PI
CHRONIC CONVECTION ENHANCED DELIVERY (CED) OF TOPOTECAN FOR GLIOBLASTOMA$624,087
R01 · FY2012 · CA · contact PI
TOPOTECAN BY INTRACEREBRAL CLYSIS FOR BRAIN TUMORS$469,759
R01 · FY2006 · CA · contact PI
TOPOTECAN BY INTRACEREBRAL CLYSIS FOR BRAIN TUMORS$472,488
R01 · FY2005 · CA
TOPOTECAN BY INTRACEREBRAL CLYSIS /TREATMENT OF PRIMARY MALIGNANT BRAINTUMOR$29,999
M01 · FY2005 · RR
TOPOTECAN BY INTRACEREBRAL CLYSIS FOR BRAIN TUMORS$464,165
R01 · FY2004 · CA
TOPOTECAN BY INTRACEREBRAL CLYSIS FOR BRAIN TUMORS$455,535
R01 · FY2003 · CA
TOPOTECAN BY INTRACEREBRAL CLYSIS FOR BRAIN TUMORS$461,502
R01 · FY2002 · CA
RECOMBINANT CHIMERIC PROTEIN FOR RECURRENT ASTROCYTOMA$192,910
M01 · FY2002 · RR
RECOMBINANT CHIMERIC PROTEIN FOR RECURRENT ASTROCYTOMA$192,910
M01 · FY2001 · RR
RECOMBINANT CHIMERIC PROTEIN FOR RECURRENT ASTROCYTOMA$0
M01 · FY2001 · RR
INTRATUMORAL/INTERSTITIAL THERAPY WITH HN-6600 IN REFRACOTRY GLIOBLASTOMA$121,168
M01 · FY2000 · RR
RECOMBINANT CHIMERIC PROTEIN FOR RECURRENT ASTROCYTOMA$0
M01 · FY2000 · RR
RECOMBINANT CHIMERIC PROTEIN FOR RECURRENT ASTROCYTOMA$0
M01 · FY2000 · RR